(Q35168443)

6 August 2017

1 reference

title

Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma (English)

1 reference

6 August 2017

1 reference

William E Berger

1

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Annals of Allergy, Asthma & Immunology

6 August 2017

published in

1 reference

6 August 2017

volume

90

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

583-91; quiz 591-2, 659

1 reference

The health economics of asthma and rhinitis. I. Assessing the economic impact

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

(S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Activated, cytotoxic CD8(+) T lymphocytes contribute to the pathology of asthma death

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

A novel role for murine IL-4 in vivo: induction of MUC5AC gene expression and mucin hypersecretion.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

(S)-albuterol increases the production of histamine and IL-4 in mast cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Effects of albuterol enantiomers on in vitro bronchial reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Effects of S-salbutamol on human isolated bronchus

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Enantioselective disposition of salbutamol in man following oral and intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Pharmacokinetics of (R,S)-Albuterol after aerosol inhalation in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Stereoselective pharmacokinetics of S-salbutamol after administration of the racemate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Salbutamol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Ipratropium bromide added to asthma treatment in the pediatric emergency department

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Levalbuterol and racemic albuterol: are there therapeutic differences?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Levalbuterol has not been established to have therapeutic advantage over racemic albuterol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Importance of calcium in citric acid-induced airway constriction.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Calcium chelators increase airway responsiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

The influence of ipratropium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Effect of inhaled preservatives on asthmatic subjects. II. Benzalkonium chloride

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

A national estimate of the economic costs of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

The cost of asthma in the emergency department and hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Observations on the effects of aerosolized albuterol in acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

Pediatric asthma deaths in Victoria: the mild are at risk

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961859-5

7 January 2021

10.1016/S1081-1206(10)61859-5

Identifiers

DOI

1 reference

6 August 2017

1 reference